Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Sharps Technology Inc. (NASDAQ:STSS) held a special meeting of stockholders on Tuesday. According to a press release statement filed with the Securities and Exchange Commission, stockholders approved all proposals presented at the meeting. The company, currently valued at approximately $154 million, has faced significant market challenges, with its stock down over 99% year-to-date according to InvestingPro data.
The company reported that 17,779,090 shares, or approximately 66.9% of the 26,600,848 shares eligible to vote as of September 16, 2025, were represented either in person or by proxy, constituting a quorum. Despite recent market volatility, InvestingPro analysis shows the company maintains a healthy current ratio of 4.35, indicating strong short-term liquidity position.
Stockholders elected Annemarie Tierney to the board of directors. She will serve until her successor is elected at the 2026 annual meeting or until her earlier resignation or removal. The vote count for Tierney was 17,770,289 shares in favor, 8,801 shares withheld, and no broker non-votes.
Shareholders also approved, in accordance with Nasdaq Listing Rule 5635(a), the issuance of up to 49,673,120 shares of common stock upon exercise of certain warrants. This includes 24,836,560 shares issuable upon exercise of Cryptocurrency Pre-Funded Warrants and 24,836,560 shares upon exercise of Cryptocurrency Stapled Warrants. The proposal received 17,750,927 votes in favor, 27,713 against, 450 abstentions, and no broker non-votes.
A separate proposal to issue 6,321,367 shares of common stock upon the exercise of warrants issued to Sol Markets was also approved. The vote tally was 17,743,259 shares for, 35,546 against, 285 abstentions, and no broker non-votes.
Stockholders further authorized the company to address any other business properly presented at the meeting and to adjourn the meeting if necessary. This proposal was approved with 16,802,916 votes for, 51,835 against, and 924,339 abstentions.
Sharps Technology , based in Melville, NY, is listed on the Nasdaq Capital Market under the symbols STSS and STSSW. While the company reported an EBITDA of -$10.23 million in the last twelve months, InvestingPro analysis suggests the stock is currently trading below its Fair Value. The information in this article is based on a press release statement filed with the SEC. For deeper insights into Sharps Technology’s financial health and 12 additional ProTips, visit InvestingPro.
In other recent news, Sharps Technology has announced a significant $100 million stock repurchase program, which has been approved by the board of directors. The company has engaged Cantor Fitzgerald to facilitate the repurchase of shares in the open market or through negotiated transactions. Additionally, Sharps Technology has expanded its digital asset treasury strategy by collaborating with Coinbase Global, acquiring over 2 million SOL tokens valued at more than $400 million. The company has also reached a confidential settlement agreement to resolve ongoing litigation with several parties, including Barry Berler and Plastomold Industries, without any admission of fault or liability. Furthermore, Sharps Technology has extended the deadline for filing its resale registration statement with the SEC, following a waiver and consent agreement with certain security holders. These developments highlight the company’s strategic moves in financial management and legal matters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.